Preliminary results – Revenue in the fourth quarter of 2020
Revenues in the fourth quarter of 2020 are expected to total $ 12.5 to 12.8 million, a growth of 28% to 31% (and a growth of 43% to 46%, excluding a one-time transaction of $ 1 million in 2019), compared to revenues of $ 9.8 million Dollars in the fourth quarter of 2019.
o WatchPAT revenue in the fourth quarter is expected to total $ 12.0 to $ 12.3 million, 32% to 35% growth (and 48% to 52% growth in the $ 1 million one-time deal neutralization in 2019), compared to $ 9.1 million In the corresponding quarter in 2019.
o WatchPAT revenue in the fourth quarter is expected to total $ 10.0 to 10.3 million, a growth of 36% to 40% (and a growth of 58% to 63% in the neutralization of a one-time transaction of $ 1 million in 2019), compared to 7.3 $ 1 million in the same quarter in 2019.
Preliminary results – Revenue in the whole of 2020
Revenues in 2020 are expected to total $ 40.8 to $ 41.1 million, a growth of approximately 31% (and a growth of 35% to 36% in the neutralization of a one-time transaction of $ 1 million in 2019), compared to revenues of $ 31.3 million in 2019.
o WatchPAT’s revenues in 2020 are expected to total $ 38.6 to 38.9 million, a growth of 33% to 34% (and a growth of 38% to 39% in the neutralization of a one-time transaction of $ 1 million in 2019), compared to $ 29.0 million in 2019.
o WatchPAT revenue in the U.S. in 2020 is expected to total $ 31.6 million to $ 31.9 million, a growth of 41% to 42% (and a growth of 48% to 49% in the neutralization of a one-time transaction of $ 1 million in 2019), compared to $ 22.4 million. Million million in 2019.
“Continuing the strong third quarter we experienced, the growth trend continued in the fourth quarter as well, largely thanks to the U.S. U.S. sleep business from existing and new customers. “We continue to believe that the transition to home care is accelerating the implementation of our programs to make accessible to many of the 80% of undiagnosed patients, who are estimated to suffer from sleep apnea in the US and the rest of the world,” he said. Gilad Glick, President and CEO of Itamar Medical.
“The company as a whole continues to focus on our mission to improve the diagnosis and treatment of sleep apnea in a safe manner, alongside advancing options to support the management of the cumulative and long-term burden resulting from cardiovascular disease and chronic obstructive pulmonary disease.”
The financial results discussed in this announcement are preliminary and represent the latest information available to the Company’s management for the fourth quarter and 2020, and are subject to further internal audits and audits by the Company’s auditors.
The Company will report the full results for the fourth quarter and for 2020 on Tuesday, March 2, 2021. The Company’s management will hold a conference call to discuss the financial results, on the same day at 15:00 Israel time.